Tags

Type your tag names separated by a space and hit enter

Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.

Abstract

BACKGROUND

We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers.

METHODS

Twenty-seven subjects were randomized in a 2 : 1 ratio to either 1.3 g of EPA + DHA daily or placebo.

RESULTS

At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean +/- SD,% weight)-EPA: 0.3 +/- 0.2, DHA: 2.9 +/- 2.0, and ratio of n-6/n-3 PUFA: 4.2 +/- 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte-EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma-EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 +/- 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 +/- 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted.

CONCLUSIONS

Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Nephrology, Indiana University School of Medicine, Indianapolis IN, USA.

    , , , ,

    Source

    MeSH

    C-Reactive Protein
    Dietary Supplements
    Docosahexaenoic Acids
    Double-Blind Method
    Eicosapentaenoic Acid
    Female
    Fish Oils
    Humans
    Male
    Middle Aged
    Pilot Projects
    Renal Dialysis

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17623719

    Citation

    Saifullah, Akber, et al. "Oral Fish Oil Supplementation Raises Blood Omega-3 Levels and Lowers C-reactive Protein in Haemodialysis Patients--a Pilot Study." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 22, no. 12, 2007, pp. 3561-7.
    Saifullah A, Watkins BA, Saha C, et al. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study. Nephrol Dial Transplant. 2007;22(12):3561-7.
    Saifullah, A., Watkins, B. A., Saha, C., Li, Y., Moe, S. M., & Friedman, A. N. (2007). Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 22(12), pp. 3561-7.
    Saifullah A, et al. Oral Fish Oil Supplementation Raises Blood Omega-3 Levels and Lowers C-reactive Protein in Haemodialysis Patients--a Pilot Study. Nephrol Dial Transplant. 2007;22(12):3561-7. PubMed PMID: 17623719.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study. AU - Saifullah,Akber, AU - Watkins,Bruce A, AU - Saha,Chandan, AU - Li,Yong, AU - Moe,Sharon M, AU - Friedman,Allon N, Y1 - 2007/07/10/ PY - 2007/7/12/pubmed PY - 2008/5/14/medline PY - 2007/7/12/entrez SP - 3561 EP - 7 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol. Dial. Transplant. VL - 22 IS - 12 N2 - BACKGROUND: We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers. METHODS: Twenty-seven subjects were randomized in a 2 : 1 ratio to either 1.3 g of EPA + DHA daily or placebo. RESULTS: At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean +/- SD,% weight)-EPA: 0.3 +/- 0.2, DHA: 2.9 +/- 2.0, and ratio of n-6/n-3 PUFA: 4.2 +/- 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte-EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma-EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 +/- 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 +/- 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted. CONCLUSIONS: Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit. SN - 0931-0509 UR - https://www.unboundmedicine.com/medline/citation/17623719/Oral_fish_oil_supplementation_raises_blood_omega_3_levels_and_lowers_C_reactive_protein_in_haemodialysis_patients__a_pilot_study_ L2 - https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfm422 DB - PRIME DP - Unbound Medicine ER -